Abstract:Funding Acknowledgements Type of funding sources: Public Institution(s). Main funding source(s): Biomedical Research Institute of Murcia (IMIB-Arrixaca) Introduction Hypertrophic cardiomyopathy (HCM) is the leading cause of sudden death in people under 35 years of age. (1) The variability of the phenotype together with its incomplete penetrance has been an obstacle to a complete understanding of the clinical spectrum and consequences of the disease. In recent years, there has been increasing interest in telomeric shortening and several authors have linked it to age-related diseases and HCM. (2, 3) Our aim was to study whether telomere length could affect the age at presentation and the severity of the HCM phenotype in genetic carriers. Methods Measurement of telomere length in circulating leukocytes (LTLc) was performed in 96 patients carrying a mutation in MYBPC3 causing HCM [58 affected (24 severely affected), 38 unaffected]. The variants included were c.2308+1G>A, p.Pro108Alafs*9, p.Arg891Alafs*160 and p.Glu258Lys, all considered founder mutations in our region. Peripheral venous blood samples were obtained from patients at the Inherited Heart Diseases Unit and stored at -80 oC after informed consent had been signed by all participants. For telomere length analysis, a telomeric restriction fragment (TRF) assay was performed using the TeloTAGGGTelomereLenghtAssay kit (Roche, 12209136001) according to the manufacturer's protocol with slight modifications. Results Our results show a lower LTLc in those affected patients with a more severe HCM phenotype compared to the affected and unaffected group (p=0.023) independently of age and sex, which are two variables that affect LTLc. Similarly, a shorter telomere length was associated with greater severity of the phenotype, with patients presenting a larger left atrial size (p=0.032), septal size (p=0.023) and greater obstruction (p=0.044). The presence of atrial fibrillation (p=0.039) and sudden death (p=0.024) was also higher in patients with shorter telomeres. Conclusions Telomere length is a variable that influences the expression of the phenotype in HCM patients carrying a MYBPC3 variant. This is an observation that supports the thesis of numerous publications linking HCM and other age-related diseases, sometimes called telomeropathies,(2) to telomere shortening. It has also been linked to non-hereditary conditions(3). This fact sheds some light on the complex phenotypic variability present in HCM, raising LTL as a promising prognostic biomarker of the disease, as has already been suggested by other authors.(4, 5, 6).Workflow in the telomere legth analysisClinical associations of LTLc

Causal relationship between leukocyte telomere length and two cardiomyopathies based on a bidirectional Mendelian randomization approach

[Advances in the Molecular Pathogenesis of Hypertrophic Cardiomyopathy].

Exploring the etiology of dilated cardiomyopathy using Mendelian randomization

Causal Relationship Between Immune Cells/Cytokines and Dilated Cardiomyopathy

Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect

[Mutation and Clinical Relevance in a Large Cohort of Unrelated Chinese Patients with Hypertrophic Cardiomyopathy].

Association between hypertrophic cardiomyopathy and variations in sarcomere gene and calcium channel gene in adults

Genetic Dissection of Hypertrophic Cardiomyopathy with Myocardial RNA-Seq

Causal association between 1400 metabolites and dilated cardiomyopathy: a bidirectional two-sample Mendelian randomization analysis

Identification of three novel pathogenic mutations in sarcomere genes associated with familial hypertrophic cardiomyopathy based on multi-omics study

Environmental Risk Factors Influence the Natural History of Familial Dilated Cardiomyopathy

Impaired Cardiomyocyte Maturation Leading to DCM: A Case Report and Literature Review.

Mutation spectrum in a large cohort of unrelated Chinese patients with hypertrophic cardiomyopathy.

Meta-Analysis of Penetrance and Systematic Review on Transition to Disease in Genetic Hypertrophic Cardiomyopathy

Early biomarkers of disease in hypertrophic cardiomyopathy: does telomere length matter?

Prevalence of Genetically Associated Dilated Cardiomyopathy: A Systematic Literature Review and Meta-Analysis

Identification and validation of pyroptosis-related genes as potential biomarkers for hypertrophic cardiomyopathy: A comprehensive bioinformatics analysis

DNA Methylome and Transcriptome Profiling Reveal Key Electrophysiology and Immune Dysregulation in Hypertrophic Cardiomyopathy

Abstract 050: Mutational Spectrum in a Cohort of Chinese Sporadic Dilated Cardiomyopathy by Next-generation Sequencing

Genetic Basis and Genotype–Phenotype Correlations in Han Chinese Patients with Idiopathic Dilated Cardiomyopathy

Genetic testing and human leukocyte antigen in patients with hypertrophic cardiomyopathy and connective tissue diseases